Role of fixed-dose combinations of antibiotics and steroids in ophthalmic surgery
DOI: 10.32364/2311-7729-2022-22-1-58-61
V.P. Nikolaenko1,2, D.F. Belov1
1City Multidisciplinary Hospital No. 2, St. Petersburg, Russian Federation
2St. Petersburg State University, St. Petersburg, Russian Federation
This paper reviews the relevance of fixed-dose combinations (FDC) of antibiotics (AB) and steroids in cataract surgery. Postoperative pharmacotherapy of phacoemulsification addresses two main issues — reducing inflammation and preventing infectious complications. Therefore, the question arises about the role of FDCs of ABs and steroids addressing both issues but in compliance with baseline principles. The most effective measure to prevent acute endophthalmitis is an intracameral injection of antibiotics at the end of surgery. Meanwhile, as early as after 10 hours, drug concentration reduces to a level that fails to prevent aqueous humor contamination with bacteria. Therefore, topical ABs, either monotherapy or FDC, are reasonable up to complete healing of phaco incisions (approximately after one week).
The authors suggest a postoperative management algorithm after uneventful phaco involving topical administration of an FDC containing 0.5% levofloxacin and 0.1% dexametha sone QID at week 1. If inflammation (conjunctival redness and cells/flare) persists, switching to dexamethasone as monotherapy QID during week 2 (and withdrawal without tapering) is recommended.
Keywords: phacoemulsification, endophthalmitis, prevention, inflammation, antibiotic, steroid, dexamethasone, fixed-dose combination, eye drops, withdrawal syndrome.
For citation: Nikolaenko V.P., Belov D.F. Role of fixed-dose combinations of antibiotics and steroids in ophthalmic surgery. Russian Journal of Clinical Ophthalmology. 2022;22(1):58–61 (in Russ.). DOI: 10.32364/2311-7729-2022-22-1-58-61.
Acknowledgements
The authors and Editorial Board are grateful to Santen LLC for providing full-text foreign articles required to write the review.
About the authors:
1,2Vadim P. Nikolaenko — Dr. Sc. (Med.), Professor of the Department of Otorhinolaryngology and Ophthalmology, Deputy Head Doctor for Ophthalmology; ORCID iD 0000-0008-6393-1289.
1Dmitrii F. Belov — ophthalmologist; ORCID iD 0000-0003-0776-4065.
1City Multidisciplinary Hospital No. 2, 5, Uchebnyy lane, St. Petersburg, 194354, Russian Federation.
2St. Petersburg State University, 7/9, Universitetskaya emb., St. Petersburg, 199106, Russian Federation.
Contact information: Dmitrii F. Belov, e-mail: belovd1990@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 07.12.2021.
2. Sharma B., Abell R.G., Arora T. et al. Techniques of anterior capsulotomy in cataract surgery. Indian J Ophthalmol. 2019;67(4):450–460. DOI: 10.4103/ijo.IJO_1728_18.
3. Cataract surgical rates. Community Eye Health. (Electronic resource.) URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820634/ (access date: 05.10.2021).
4. Wu C.M., Wu A.M., Young B.K. et al. An evaluation of cataract surgery clinical practice guidelines. Br J Ophthalmol. 2015;99:401–404. DOI: 10.1136/bjophthalmol-2014-305567.
5. Ong-Tone L., Bell A., Tan Y.Y. Practice patterns of Canadian Ophthalmological Society members in cataract surgery: 2011 survey. Can J Ophthalmol. 2012;47(2):124–130. DOI: 10.1016/j.jcjo.2012.01.012.
6. Matossian C., Makari S., Potvin R. Cataract surgery and methods of wound closure: a review. Clin Ophthalmol. 2015;9:921–928. DOI: 10.2147/OPTH.S83552.
7. Han K.E., Chung W.S., Kim T.I. et al. Epithelial wound healing after cataract surgery comparing two different topical fluoroquinolones. Yonsei Med J. 2014;55(1):197–202. DOI: 10.3349/ymj.2014.55.1.197.
8. Barry P., Cordoves L., Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery. 2013. (Electronic resource.) URL: https://www.escrs.org/downloads/Endophthalmitis-Guidelines.pdf (access date: 05.10.2021).
9. Sheu S.J. Endophthalmitis. Korean J Ophthalmol. 2017;31(4):283–289. DOI: 10.3341/kjo.2017.0036.
10. Lundström M., Wejde G., Stenevi U. et al. Endophthalmitis after cataract surgery: a nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology. 2007;114(5):866–870. DOI: 10.1016/j.ophtha.2006.11.025.
11. Pershing S., Lum F., Hsu S. et al. Endophthalmitis after Cataract Surgery in the United States: A Report from the Intelligent Research in Sight Registry, 2013–2017. Ophthalmology. 2020;127(2):151–158. DOI: 10.1016/j.ophtha.2019.08.026.
12. Wejde G., Samolov B., Seregard S. et al. Risk factors for endophthalmitis following cataract surgery: a retrospective case-control study. J Hosp Infect. 2005;61(3):251–256. DOI: 10.1016/j.jhin.2005.04.016.
13. Montan P.G., Wejde G., Setterquist H. et al. Prophylactic intracameral cefuroxime. Evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg. 2002;28(6):982–987. DOI: 10.1016/s0886-3350(01)01270-6.
14. Aragona P., Postorino E.I., Aragona E. Post-surgical management of cataract: Light and dark in the 2020s. Eur J Ophthalmol. 2021;31(2):287–290. DOI: 10.1177/1120672120963458.
15. Pham D.T. Leitlinie zur Prophylaxeund Therapie von Endophthalmitiden, 2005. (Electronic resource.) URL: http://www.dgii.org/uploads/pdfs/LeitlinieEndophthalmitis_2005.pdf (access date: 01.10.2021).
16. Bratzler D.W., Dellinger E.P., Olsen K.M. et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283. DOI: 10.2146/ajhp120568.
17. Yao K., Zhang Z., Yang Y.H. et al. Aqueous humor penetration of topically applied ofloxacin, ciprofloxacin and tobramycin. Zhonghua Yan Ke Za Zhi. 2003;39(12):736–739. PMID: 14769225.
18. Luthardt K., Beck R., Hehl E.M. et al. Corneal penetration of various aminoglycosides and quinolones. Klin Monbl Augenheilkd. 1998;213(3):141–146. DOI: 10.1055/s-2008-1034964.
19. Packer M., Chang D.F., Dewey S.H. et al. Prevention, diagnosis, and management of acute postoperative bacterial endophthalmitis. J Cataract Refract Surg. 2011;37(9):1699–1714. DOI: 10.1016/j.jcrs.2011.06.018.
20. De Kaspar M.H., Kreutzer T.C., Aguirre-Romo I. et al. A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. Am J Ophthalmol. 2008;145(1):136–142. DOI: 10.1016/j.ajo.2007.08.031.
21. Bucci F.A. Jr. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Am J Ophthalmol. 2004;137(2):308–312. DOI: 10.1016/j.ajo.2003.08.057.
22. Holland E.J., Fingeret M., Mah F.S. Use of topical steroids in conjunctivitis: a review of the evidence. Cornea. 2019;38(8):1062–1067. DOI: 10.1097/ICO.0000000000001982.
23. Figus M., Posarelli C., Romano D. et al. Aqueous humour concentrations after topical apPlication of combinEd levofloxacin-dexamethasone eye dRops and of its single components: a randoMised, assEssor-blinded, parallel-group study in patients undergoing cataract surgery: the iPERME study. Eur J Clin Pharmacol. 2020;76(7):929–937. DOI: 10.1007/s00228-020-02863-7.
24. Porela-Tiihonen S., Kokki H., Kaarniranta K. et al. Recovery after cataract surgery. Acta Ophthalmol. 2016;94(2):1–34. DOI: 10.1111/aos.13055.
25. WHO. Worldwide country situation analysis: response to antimicrobial resistance. (Electronic resource.) URL: https://www.who.int/drugresistance/documents/situationanalysis/en (access date: 01.10.2021).
26. Bandello F., Coassin M., Di Zazzo A. et al. One week of levofloxacin plus dexamethasone eye drops for cataract surgery: an innovative and rational therapeutic strategy. Eye (Lond). 2020;34(11):2112–2122. DOI: 10.1038/s41433-020-0869-1.
27. Bhattacharyya A., Kaushal K., Tymms D.J., Davis J.R. Steroid withdrawal syndrome after successful treatment of Cushing’s syndrome: a reminder. Eur J Endocrinol. 2005;153(2):207–210. DOI: 10.1530/eje.1.01953.
28. Астахов Ю.С., Николаенко В.П. Офтальмология. Фармакотерапия без ошибок. М.: Е-ното; 2021. [Astakhov Yu.S., Nikolaenko V.P. Ophthalmology. Pharmacotherapy without mistakes. M.: E-noto; 2021 (in Russ.)].
29. Chodosh J. The herpetic eye disease study: topical corticosteroid trial for herpes simplex stromal keratitis: a paradigm shifting clinical trial. Ophthalmology. 2020;127(4S):S3–S4. DOI: 10.1016/j.ophtha.2019.09.044.
30. Koronis S., Stavrakas P., Balidis M. et al. Update in treatment of uveitic macular edema. Drug Des Devel Ther. 2019;13:667–680. DOI: 10.2147/DDDT.S166092.
31. Blondeau J.M. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004;49(2):S73–78. DOI: 10.1016/j.survophthal.2004.01.005.
32. Sanders C.C. Review of preclinical studies with ofloxacin. Clin Infect Dis. 1992;14(2):526–538. DOI: 10.1093/clinids/14.2.526.
33. Patel S.C., Spaeth G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26(3):233–236.
34. Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–423. DOI: 10.1136/bjo.86.4.418.
35. Xing Y., Zhu L., Zhang K. et al. The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis. PLoS One. 2020;15(2):e0229682. DOI: 10.1371/journal.pone.0229682.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
